Statistical evaluation of decrease in anti-CCP and RF serum levels in patients with rheumatoid arthritis in relation to clinical improvement after infliximab treatment
| ACR response | Anti-CCP (IU) | RF (IU) | ||
|---|---|---|---|---|
| Week 0 | Week 24 | Week 0 | Week 24 | |
| Values are mean (SD). | ||||
| *p<0.01. | ||||
| ACR, American College of Rheumatology (criteria for response); CCP, cyclic citrullinated peptide; RF, rheumatoid factor. | ||||
| <20% (n = 21) | 116 (62) | 106 (66) | 445 (466) | 321 (332) |
| ACR 20 (n = 22) | 94 (59) | 77 (62)* | 359 (310) | 231 (247)* |
| ACR 50 (n = 13) | 87 (66) | 71 (67)* | 325 (343) | 189 (210)* |
| ACR 70 (n = 4) | 61 (74) | 45 (73) | 466 (439) | 265 (303) |